Autopsy report · NCT00519532
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
Cause of deathDrug or device supply
“Due to clinical trial supplies shortage”
Life of this trial
- Registered 1 month after it had already started.
- Ran for about 1 year 10 months before it stopped.
- 84 participants enrolled.
- Results were posted on the registry 11 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- UCB Pharma
- Sponsor type
- Industry
- Conditions
- Parkinson's Disease
- Interventions
- Rotigotine
- Participants
- 84
- Sites
- 21
- Countries
- Australia, Finland, Germany, Hungary, Italy, New Zealand, Poland, South Africa, Spain, United Kingdom, United States
Trials that died the same way
- Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers
“clinical trial have encountered difficulties enrolling a sufficient number of patients” - Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain
“The clinical trial has ended prematurely due to low patient recruitment” - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
“Low recruitment activities of clinical trial sites.” - INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
“Terminated due to clinical trial material production delays” - A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema
“The trial was stopped early due to insufficient study drug supply and study funding constraints”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.